The lesson that entrepreneurs and VCs seem to be taking from the fast-paced ophthalmology sector is the need for shorter development time frames and clinical candidates with reduced risk. Among others, MacuSight, Danube, and Lux, profiled here, are to one extent or another revisiting the existing pharmacopeia to test ophthalmic indications for existing compounds.

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2006. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.

In this issue, we present another installment of our quarterly review of dealmaking-for January-March 2006. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.

Instrument makers have made big money off the genomics revolution. But as the research market slows, companies are looking for new business opportunities. One area ripe for development: the molecular diagnostics market.